Literature DB >> 22289637

Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma.

Yu-Jie Liu1, Guo-Pei Zhu, Xi-Yin Guan.   

Abstract

To compare the role of CTCAE version 4.0 (v4.0) and version 3.0 (v3.0) in assessing chemoradiation-induced oral mucositis (OM) for locally advanced nasopharyngeal carcinoma (LA-NPC). Patients with LA-NPC were recruited into the study. All eligible participants received docetaxel and cisplatin-based induction chemotherapy followed by intensity modulated radiation therapy concurrent with cisplatin. OM was assessed before and weekly during radiotherapy (RT), using CTCAE v3.0 (clinical exam) and v4.0 separately. OM-related quality of life (QOL) was also evaluated in these patients with the EORTC Quality of Life Questionnaire - Head and Neck module (QLQ-H&N35). From June 2010 to February 2011, 23 eligible patients were enrolled. A highly significant correlation (rho=0.838, p=0.000) and a non-significant difference (p=0.167) in OM grades were found between the two CTCAE versions. However, the trend lines showed that the mean grade determined by CTCAE v3.0 reached a plateau while the mean grade determined by v4.0 continued to increase after the fourth week during RT. Changing trends of several QOL subscale mean scores were similar to that of OM mean grade evaluated by CTCAE v4.0. Both grades of the two CTCAE versions were significantly and positively correlated with scores of several QOL subscales. Nonetheless, the correlation coefficients related to CTCAE v4.0 were higher than those related to v3.0 (rho: 0.727-0.865 versus 0.727-0.778). CTCAE v4.0 could serve as a good surrogate for v3.0 (clinical exam) in assessing chemoradiation-induced oral mucositis. Moreover, CTCAE v4.0 has a few subtle advantages over v3.0 under some circumstances such as delegating QOL. However, there is still no "gold standard" assessment scale for oral mucositis. Therefore, the appropriate tool should be carefully chosen according to the purpose of assessment.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22289637     DOI: 10.1016/j.oraloncology.2012.01.004

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  32 in total

1.  Evaluation of the efficacy and safety of a neoadjuvant gemcitabine and nedaplatin regimen followed by radiotherapy or concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma.

Authors:  Ting Jin; Xiao-Zhong Chen; Jian-Jiang Liu
Journal:  Oncol Lett       Date:  2015-06-10       Impact factor: 2.967

2.  Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events.

Authors:  Tamara P Miller; Brian T Fisher; Kelly D Getz; Leah Sack; Hanieh Razzaghi; Alix E Seif; Rochelle Bagatell; Peter C Adamson; Richard Aplenc
Journal:  Pediatr Blood Cancer       Date:  2019-04-09       Impact factor: 3.167

Review 3.  Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck.

Authors:  Carol Ann Milazzo-Kiedaisch; Joanne Itano; Pinaki R Dutta
Journal:  Clin J Oncol Nurs       Date:  2016-12-01       Impact factor: 1.027

4.  TOXICAN: a guide for grading dermatological adverse events of cancer treatments.

Authors:  L Peuvrel; J Cassecuel; C Bernier; G Quéreux; M Saint-Jean; M Le Moigne; C Frénard; A Khammari; B Dréno
Journal:  Support Care Cancer       Date:  2018-03-12       Impact factor: 3.603

5.  Efficacy of kangfuxin liquid on radiotherapy-induced oral mucositis for patients with head and neck squamous cell carcinoma and its effect on salivary glands and immune function.

Authors:  Hao Yuan; Jiajia Su; Junyin Tan; Yan Wei
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

6.  Effect of polypharmacy and potentially inappropriate medications on treatment and posttreatment courses in elderly patients with head and neck cancer.

Authors:  Jun Woo Park; Jong-Lyel Roh; Sang-Wook Lee; Sung-Bae Kim; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  J Cancer Res Clin Oncol       Date:  2016-01-07       Impact factor: 4.553

7.  Clinical application effect of Pembrolizumab in the treatment of advanced cutaneous malignant melanoma.

Authors:  Lei Fu; Hui Zhang; Jingwen Jiang; Xuewu Chen; Lang Chen; Hui Gong
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

8.  Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma.

Authors:  Tomoko Aoki; Naoshi Nishida; Kazuomi Ueshima; Masahiro Morita; Hirokazu Chishina; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Yasunori Minami; Akira Yamada; Keitaro Sofue; Masakatsu Tsurusaki; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2021-08-19       Impact factor: 11.740

9.  Supportive Management of Mucositis and Metabolic Derangements in Head and Neck Cancer Patients.

Authors:  Marcelo Bonomi; Katharine Batt
Journal:  Cancers (Basel)       Date:  2015-09-03       Impact factor: 6.639

10.  Corticosteroid treatment for community-acquired pneumonia--the STEP trial: study protocol for a randomized controlled trial.

Authors:  Claudine A Blum; Nicole Nigro; Bettina Winzeler; Isabelle Suter-Widmer; Philipp Schuetz; Matthias Briel; Roland Bingisser; Werner Zimmerli; Elke Ullmer; Hanno Elsaesser; Philip Tarr; Sebastian Wirz; Robert Thomann; Eveline Hofmann; Nicolas Rodondi; Hervé Duplain; Dieter Burki; Beat Mueller; Mirjam Christ-Crain
Journal:  Trials       Date:  2014-06-28       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.